Skip to content
Screener

Idexx Laboratories IDXX Q2 2026 earnings

Reported August 4, 2026 · Before market open

Revenue$1.2BBeat by $16.4M
Adjusted EPS$4.07Beat by $0.13
Revenue estimate$1.2B
EPS estimate$3.94
“Our second quarter results reflect the strength of our Technology for Life strategy, with continued innovation across our Catalyst, Fecal Dx, and IDEXX inVue Dx platforms supporting deeper customer adoption and higher diagnostic utilization. This is the kind of durable, compounding growth we're building for the long term, helping veterinarians see more and do more for their patients while creating lasting value for our shareholders.”
Mike Erickson

Earnings data and commentary were extracted with AI from company filings and may contain errors. Verify important details in the filing.

Next report

Nov 2, 2026 (in 2 months)
Revenue estimate$1.2B
EPS estimate$3.71

Financials

Q2 2026

Income statement

See full
Revenue$1.2B+9.7%
Gross profit$779.1M+12.1%
Operating income$425.6M+14.1%
Net income$338.4M+15.1%
EPS (diluted)$4.27+17.6%

Balance sheet

See full
Cash & equivalents$196.9M+19.6%
Total debt$449.9M-31.7%
Total equity$1.6B+10.5%
Total assets$3.4B+3.3%

Cash flow

See full
Operating cash flow$347.2M+86.9%
CapEx$24.6M-27.7%
Free cash flow$322.5M+113%

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$43.6B-15.0%
Enterprise value$43.85B-15.3%
P/E38.3×-13.8×
P/S9.6×-3.1×

Profitability

See full
Gross margin62.4%+0.9pp
Operating margin32%+0.9pp
Net margin25%+0.6pp
FCF margin27.5%+8.1pp

Returns & leverage

See full
Return on equity74.2%+9.3pp
Debt / equity0.3×-0.2×
Current ratio1.2×+0.1×

Segments

By product

See full
IDEXX VetLab consumables$430.3M+14.7%
Reference laboratory diagnostic and consulting services$406.7M+10.6%
Rapid assay products$101.6M+1.3%
Recurring revenue$76.3M+10.7%
CAG Diagnostics capital - instruments$47.2M-19.5%

By segment

See full
Water segment revenue$58.6M+14.8%

FAQ

When did Idexx Laboratories report Q2 2026 earnings?
Idexx Laboratories (IDXX) reported Q2 2026 earnings on August 4, 2026 before market open.
What were Idexx Laboratories's Q2 2026 revenue and EPS?
Idexx Laboratories reported revenue of $1.2B and adjusted eps of $4.07 for Q2 2026.
Did Idexx Laboratories beat estimates in Q2 2026?
Revenue beat the consensus estimate of $1.2B by $16.4M. EPS beat the consensus estimate of $3.94 by $0.13.
How did Idexx Laboratories's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 9.7% from $1.1B a year earlier.
Where can I find Idexx Laboratories's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-090033) and the 10-Q periodic report (0000874716-26-000123) directly on SEC EDGAR. The filing index links above go to sec.gov.